NCT07612280
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07612280
Title Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jubilant Therapeutics Inc.
Indications
Therapies
Age Groups: senior
Covered Countries AUS

Facility Status City State Zip Country Details
St. Vincent's Hospital Sydney Limited RECRUITING Sydney New South Wales 2010 Australia Details
Macquarie University RECRUITING Sydney New South Wales 2109 Australia Details
Royal Adelaide Hospital RECRUITING Adelaide South Australia 5000 Australia Details
St Vincent's Hospital (Melbourne) RECRUITING Melbourne Victoria 3065 Australia Details
Monash Medical Centre RECRUITING Melbourne Victoria 3168 Australia Details
The Perth Blood Institute Limited RECRUITING Perth Western Australia 6000 Australia Details
Hollywood Private Hospital RECRUITING Nedlands 6009 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field